Search Results (5)

The synthesis and crystal structure of 4,11-dimethyl-2,13-di-m-tolyltribenzo[b,e,g][1,4]dioxocine-7,8-dicarbonitrile are reported. X-ray diffraction analysis reveals a rigid dioxocine core with m-tolyl substituents adopting torsional angles of 25–40°. The crystal packing is stabilized by C-H···N hydrogen bonds (2.6 Å) and π-π stacking interactions (3.4 Å) between dicarbonitrile groups, forming dimeric motifs. These structural insights provide a foundation for designing dioxocine-based functional materials. Full article

Glutamine metabolism is an important hallmark of several cancers with demonstrated antitumor activity in glioblastoma cancer cells (GBM). GBM cells regulate glutamine and use it as a major energy source for their proliferation through the glutaminolysis process. Enzymes, such as glutaminase in glutaminolysis, can be targeted by small-molecule inhibitors, thus exhibiting promising anticancer properties. The resistance to glutaminolysis demands the development of new therapeutic molecules to overcome drug resistance. Herein, we have reported a novel library of constrained methanodibenzo[b,f][1,5]dioxocin derivatives as glutaminase (GLS) inhibitors and their anti-GBM potential. The library consisting of seven molecules was obtained through self-condensation of 2′-hydroxyacetophenones, out of which three molecules, namely compounds 3, 5, and 6, were identified with higher binding energy values ranging between −10.2 and −9.8 kcal/mol with GLS (PDB ID; 4O7D). Pharmacological validation of these compounds also showed a higher growth inhibition effect in GBM cells than the standard drug temozolomide (TMZ). The most promising compound, 6, obeyed Lipinski’s rule of five and was identified to interact with key residues Arg³⁰⁷, Asp³²⁶, Lys³²⁸, Lys³⁹⁹, and Glu⁴⁰³ of GLS. This compound exhibited the best cytotoxic effect with IC₅₀ values of 63 µM and 83 µM in LN229 and SNB19 cells, respectively. The potential activation of GLS by the best-constrained dibenzo[b,f][1,5]dioxocin in the tested series increased apoptosis via reactive oxygen species production in both GBM cells, and exhibited anti-migratory and anti-proliferative properties over time in both cell lines. Our results highlight the activation mechanism of a dibenzo[b,f][1,5]dioxocin from the structural basis and demonstrate that inhibition of glutaminolysis may facilitate the pharmacological intervention for GBM treatment. Full article

The preparation of unprecedented 6,12-disubstituted methanodibenzo[b,f][1,5]dioxocins from pyrrolidine catalyzed self-condensation of 2′-hydroxyacetophenones is herein described. This method provides easy access to this highly bridged complex core, resulting in construction of two C–O and two C–C bonds, a methylene bridge and two quaternary centers in a single step. The intricate methanodibenzo[b,f][1,5]dioxocin compounds were obtained in up to moderate yields after optimization of the reaction conditions concerning solvent, reaction times and the use of additives. Several halide substituted methanodibenzo[b,f][1,5]dioxocins could be prepared from correspondent 2′-hydroxyacetophenones. Full article

A series of caffeic acid amides D₁-D₁₇ bearing 2,3,4,5-tetrahydrobenzo-[b][1,4]dioxocine units has been synthesized and their biological activities evaluated for potential antiproliferative and EGFR inhibitory activity. Of all the compounds studied, compound D₉ showed the most potent inhibitory activity (IC₅₀ = 0.79 μM for HepG2 and IC₅₀ = 0.36 μM for EGFR). The structures of compounds were confirmed by ¹H-NMR, ESI-MS and elemental analysis. Among all, the structure of compound D₉ ((E)-N-(4-ethoxyphenyl)-3-(2,3,4,5-tetrahydrobenzo[b][1,4]dioxocin-8-yl)acrylamide) was also determined by single-crystal X-ray diffraction analysis. Compound D₉ was found to be a potential antitumor agent according to biological activity, molecular docking, apoptosis assay and inhibition of HepG2. Full article